Clin Shoulder Elb Search

CLOSE


Clin Shoulder Elb > Volume 29(3); 2026 > Article
Queenan, Shehadeh, Kim, Lanham, and Updegrove: Hemophilia increases risk of bleeding and thromboembolism after total shoulder arthroplasty

Abstract

Background

Hemophilia, including hemophilia A, hemophilia B, and related coagulation disorders, poses unique perioperative challenges in total shoulder arthroplasty (TSA). Factor replacement and postoperative immobilization may paradoxically increase thromboembolic risk, yet the literature defining venous thromboembolism (VTE) and other complications in this population is limited. We aimed to characterize 90-day postoperative outcomes among patients with hemophilia undergoing TSA.

Methods

A multicenter electronic health record database (TriNetX Global) was retrospectively analyzed to identify patients undergoing TSA between December 2005 and December 2025. Patients with hemophilia were compared to propensity-matched controls based on relevant comorbidities. Primary outcomes included 90-day rates of readmission, periprosthetic joint infection (PJI), revision surgery, and bleeding complications. Secondary outcomes included deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, pneumonia, acute kidney injury (AKI), and urinary tract infection (UTI). Odds ratios with 95% CIs were calculated. P-value <0.05 was considered statistically significant.

Results

Compared with matched controls, patients with hemophilia had significantly higher rates of readmission and revision surgery. They also demonstrated increased risk of bleeding complications and thromboembolic events, including DVT, PE, VTE, and stroke. Higher rates of postoperative medical complications, including pneumonia, AKI, and UTI, as well as greater postoperative opioid prescription utilization were observed. Rates of PJI did not differ between groups.

Conclusions

Patients with hemophilia are at significantly increased risk of thromboembolic complications and revision surgery following TSA. Prospective studies evaluating preoperative optimization and management of modifiable VTE risk factors are warranted.

Level of evidence

III.

INTRODUCTION

As the volume of total shoulder arthroplasty (TSA) continues to grow, it has become increasingly important to characterize perioperative outcomes in medically complex patient populations [1-5]. Hemophilia is a rare congenital deficiency of clotting factors VIII or IX that results in prolonged or uncontrolled bleeding. Recurrent intra-articular bleeding can lead to hemophilic arthropathy, a condition characterized by joint remodeling and chronic pain. This condition most often affects the knee (45%) and elbow (30%), and less frequently the shoulder (3%) [6,7]. Although routine clotting factor replacement therapy has markedly reduced the incidence of hemophilic arthropathy, advanced disease remains severe and debilitating [7]. In advanced hemophilic arthropathy, progressive joint destruction may require major orthopaedic procedures, including joint arthroplasty, to prevent irreversible bone loss and restore function [8,9].
Although individuals with hemophilia are generally considered to have a low baseline risk for venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), major surgery introduces several thrombotic risk factors. These include perioperative immobilization, endothelial injury, and clotting factor replacement, which may paradoxically increase VTE risk in this patient population [8,10]. While outcomes following lower extremity arthroplasty in patients with hemophilia have been reported, the perioperative risk profile associated with TSA remains poorly defined [11-15].
In this study, we characterized the perioperative complications of patients with hemophilia undergoing total shoulder arthroplasty compared with matched controls. We hypothesized that patients with hemophilia experience higher rates of thromboembolic and medical complications following TSA.

METHODS

This study was exempt from institutional review board review because the TriNetX database contains fully de-identified patient data. Accordingly, the requirement for informed consent was waived.

Data

We utilized the TriNetX database, a large research platform that collects de-identified health records from over 100 healthcare institutions worldwide. This database offered detailed clinical information, including diagnostic codes, procedural data, medications, and laboratory values extracted directly from clinical records. Database queries of the Global Collaborative Network were performed on December 3, 2025, using Current Procedural Terminology (CPT), Systematized Nomenclature of Medicine (SNOMED) and International Classification of Diseases, Tenth Revision (ICD-10) codes (Supplementary Table 1).

Inclusion and Exclusion Criteria

We included patients at least 18 years of age undergoing TSA between December 2005 and December 2025. Patients with diagnoses of disseminated intravascular coagulation were excluded from our analysis. Patients were then stratified into two cohorts based on whether they had preoperative diagnoses of a hemophilic condition. Hemophilic conditions were defined as hereditary factor VIII, IX, and XI deficiencies, other clotting factor deficiencies, von Willebrand disease, and other specified or unspecified coagulation defects. One-to-one (1:1) propensity score matching was conducted via the TriNetX platform using a nearest-neighbor algorithm with a 0.01 caliper, and covariate balance was assessed using standardized mean differences, with values ≤0.1 indicating acceptable balance. Included covariates were relevant comorbidities, such as age at surgery, sex, race, type 2 diabetes mellitus, hypertension, dyslipidemia, obesity, chronic kidney disease, tobacco use, history of neoplasm, hemoglobin A1c, and body mass index [16-18].

Outcomes and Complications

Postoperative outcomes and complications were assessed until 90 days following index procedures. Primary outcomes included rates of readmission, revision surgery, incidence of periprosthetic joint infection (PJI), and bleeding complications. Secondary outcomes included the incidence of DVT, PE, VTE, pneumonia, acute kidney injury (AKI), stroke, urinary tract infection (UTI), and number of opioid prescriptions.

Data Analyses

To assess differences between patients undergoing TSA with and without hemophilia, we calculated odds ratios (ORs) and 95% CIs using the built-in TriNetX analytical tool. Continuous variables were summarized using means with standard deviations and compared using Student t-test. Categorical variables were compared using the chi-square test. P-values <0.05 were considered statistically significant.

RESULTS

Our initial query identified 88,452 patients who underwent TSA, including 2,233 patients with preoperative diagnoses of hemophilia and 86,219 without hemophilia. After propensity score matching, each cohort comprised 2,233 patients, with acceptable covariate balance between groups (Table 1).

Surgical Complications

Patients with hemophilia undergoing TSA demonstrated significantly higher rates of hospital readmission (OR, 1.79; 95% CI, 1.46–2.19; P<0.001), revision surgery (OR, 1.81; 95% CI, 1.05–3.14; P=0.031), and bleeding-related complications (OR, 3.85; 95% CI, 1.91–7.74; P<0.001) compared with matched controls (Table 2). Rates of PJI did not differ between cohorts.

Medical Complications

Patients with hemophilia experienced significantly higher rates of thromboembolic events, including DVT (OR, 4.65; 95% CI, 2.85–7.57; P<0.001), PE (OR, 5.49; 95% CI, 3.16–9.57; P<0.001), VTE (OR, 4.85; 95% CI, 2.90–8.10; P<0.001), and stroke (OR, 2.22; 95% CI, 1.31–4.79; P=0.003), compared with patients without hemophilia. Additionally, postoperative medical complications, including pneumonia (OR, 2.49; 95% CI, 1.58–3.91; P<0.001), AKI (OR, 1.92; 95% CI, 1.35–2.72; P<0.001), and UTI (OR, 1.67; 95% CI, 1.21–2.29; P=0.002), were more common in the hemophilia cohort (Table 3). Patients with hemophilia also required greater postoperative opioid prescription utilization within 90 days following TSA (P<0.001).

DISCUSSION

The principal findings of this study were that patients with hemophilia undergoing TSA have a significantly higher risk of experiencing thromboembolic events within 90 days postoperatively, including DVT, PE, VTE, and stroke. In addition, hemophilia was associated with increased rates of hospital readmission, revision surgery, bleeding, and medical complications compared with matched controls.
We found that patients with hemophilia had increased risk of thromboembolic events and bleeding complications following TSA. These findings align with prior research and reinforce the importance of perioperative planning, including preparation for potential postoperative blood transfusion and appropriate administration of clotting factor replacement therapy [11]. Although thromboembolic risk was greater in our hemophilia cohort (3.76%), it remained within the range of VTE rates reported in the general population following TSA (0.2%–16.0%) [16]. In addition, we found no significant differences in prosthetic joint infection between the groups, which is consistent with prior studies [11].
Our results challenge the traditional assumption that hemophilia primarily confers bleeding risk while protecting against thrombosis. Instead, our findings demonstrate an association between hemophilia and increased perioperative thromboembolic events. One potential explanation is a perioperative “thrombotic paradox,” in which clotting factor replacement and antifibrinolytic use may shift patients into a transient hypercoagulable state [8]. However, as our dataset does not include treatment-specific variables such as factor dosing or antifibrinolytic administration, this proposed mechanism remains speculative. Prior studies suggest that high-dose factor replacement can restore or exceed normal coagulation, increasing thrombin generation and thrombotic potential, particularly in the setting of surgical endothelial injury and postoperative immobilization [19-22]. Further investigations incorporating detailed perioperative management data are needed to clarify the underlying mechanisms driving this observed association.
The risk profile may be especially relevant in TSA, where postoperative immobilization in adduction and internal rotation differs from early mobilization protocols commonly practiced following hip and knee arthroplasty [18,23-25]. These procedure-specific factors may help explain why thromboembolic risk following TSA in patients with hemophilia appears to differ from that reported in the lower arthroplasty literature [12,18,23].
Existing studies suggest the baseline risk for VTE following TSA may be as high as 13%, despite TSA generally being considered a lower-risk procedure compared to lower extremity arthroplasty [16,17]. Several risk factors have been identified, including prolonged hospitalization and postoperative immobilization [16]. Unlike total hip arthroplasty (THA) and total knee arthroplasty (TKA), which emphasize early postoperative mobilization, postoperative protocols following TSA involve prolonged immobilization [18,23]. A cross-sectional study found that 89% of TSA postoperative protocols included sling immobilization with or without an immobilizer for four to six weeks following surgery [24,26]. Immobilization is prioritized in shoulder procedures to protect soft tissue structures, with most rehabilitation protocols delaying range-of-motion exercises until six weeks after surgery [26]. In contrast, early mobilization, weight-bearing, and ambulation are encouraged within 24–48 hours postoperatively following THA or TKA to reduce thromboembolic risk [18,25,27].
Despite these considerations, the literature investigating outcomes of TSA in patients with hemophilia remains limited [28]. A 2025 literature review identified only four articles evaluating shoulder arthroplasty in this patient population [10]. One study reported that patients with hemophilia may have an increased risk of bleeding complications and VTE following TSA, while others describe TSA as a reasonable surgical option for patients with hemophilic arthropathy [10,11]. TSA performed in patients with hemophilia represents an understudied and distinct clinical scenario in which bleeding risk, thrombosis risk, and prolonged postoperative immobilization intersect.
From a clinical perspective, these findings have important implications for preoperative counseling and perioperative planning. Surgeons should counsel patients with hemophilia undergoing TSA about the elevated risk for bleeding and the increased risk for thromboembolic and medical complications. Early involvement of hematology is essential for clotting factor replacement, including preoperative factor optimization and postoperative dose adjustments to maintain adequate hemostasis, while avoiding excessive hypercoagulability. Consideration of thromboprophylaxis strategies, including mechanical or chemoprophylaxis, should also be individualized to balance the risk for postoperative bleeding with the increased thromboembolic risks associated with surgery and postoperative immobilization. When feasible, early and structured postoperative mobilization may help mitigate thromboembolic risk, while protecting the surgical repair. Finally, close postoperative monitoring for bleeding and thromboembolic complications is warranted given the competing hemostatic risks in this patient population. The observed increases in readmission, revision surgery, and medical complications further highlight the need for multidisciplinary perioperative management to optimize outcomes following TSA in patients with hemophilia [29].
Beyond thrombotic events, patients with hemophilia experienced higher rates of bleeding-related complications, revision surgery, and postoperative opioid prescription utilization. Chronic hemophilic arthropathy and recurrent hemarthroses may contribute to joint degeneration and increased technical complexity, potentially increasing revision risk [6,7]. Higher rates of systemic complications such as pneumonia, UTI, and AKI may partially explain the increased readmission observed in this cohort. Notably, rates of PJI did not differ between groups, highlighting the heterogeneity of complication risk in this population.
This study has several limitations. We utilized data from the TriNetX research database, which compiles de-identified electronic health records across multiple institutions. While this provides a large sample size, it introduces potential inconsistencies in coding, documentation, and treatment practices, which could affect data reliability. In particular, the hemophilia cohort included patients with hemophilia A, hemophilia B, and related coagulation disorders identified through diagnostic coding, which precluded stratification by specific disorder type, disease severity, or factor replacement regimen. Hemophilic conditions were grouped to include von Willebrand disease and other clotting factor deficiencies. As these disorders differ in pathophysiology and bleeding risk, evaluating them as a single cohort may have introduced clinical heterogeneity and potentially confounded the interpretation of our results. Additionally, due to the retrospective design of our study and inherent limitations within the TriNetX database, hemophilia subgroup analyses were not performed. Variations in disease subtype and severity may have an impact on postoperative complication rates.
Next, the dataset lacked granularity in key clinical variables. Similarly, data regarding surgical indications for TSA, including fracture, arthritis, or rotator cuff arthropathy, were unavailable, which may have also influenced complication rates. Differences between primary and secondary TSA may be associated with different intraoperative and postoperative complication profiles, representing a limitation of this study. Further, TSA implant types were not accounted for due to limitations in the TriNetX database. As implant types have evolved substantially between 2005 and 2025, this factor may have influenced postoperative outcomes. In addition, some outcomes (e.g. PJI and bleeding complications) have very low event counts. Although ORs are reported, these outcomes have limited statistical power, and the results should be interpreted with appropriate caution.
Data regarding important hemophilia-specific factors, such as clotting factor replacement regimen, inhibitor status, use of antifibrinolytics, and intraoperative blood loss, were not available in the TriNetX database. As these factors could significantly influence perioperative bleeding and thromboembolic risk, the absence of this information may have impacted our results. Furthermore, some outcomes, including PJI and bleeding, had fewer than 10 reported incidences in the control group. Although the limited sample size likely reduced statistical power, several comparisons with confidence intervals were given to inform the reader of precision for estimated effects. Finally, this study only captured data within a 90-day postoperative period and did not account for long-term complications, delayed VTE events, or late-onset infections. Future prospective studies with longer follow-up periods are warranted to better characterize the perioperative risks in this unique patient population.

CONCLUSIONS

Patients with hemophilia had a significantly higher risk of developing thrombosis, including PE, DVT, and stroke, as well as bleeding complications, readmission, and revision surgery 90 days after undergoing TSA. These findings challenge prior assumptions that bleeding is the primary concern in this cohort and underscore the need for tailored perioperative management.

NOTES

Author contributions

Conceptualization: KQ, NL, GU. Data curation: KQ, THS. Formal analysis: KQ, THS, AHK, GU. Investigation: KQ, THS. Methodology: KQ, THS. Project administration: KQ, NL. Resources: KQ. Supervision: KQ, NL, GU. Writing – original draft: KQ, THS, AHK. Writing – review & editing: KQ, THS, AHK, NL, GU. All authors read and agreed to the published version of the manuscript.

Conflict of interest

None.

Funding

None.

Data availability

Contact the corresponding author for data availability.

Acknowledgments

None.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found via https://doi.org/10.5397/cise.2026.00108.
Supplementary Table 1.
Summary of codes utilized for database query
cise-2026-00108-Supplementary-Table-1.pdf

Table 1.
Patient demographics and comorbidities
Patient characteristics Hemophilia Control P-value Standard difference
Demographics
 Female 1,261 (56.47) 1,253 (56.11) 0.809 0.007
 Male 972 (43.53) 980 (43.89) 0.809 0.007
 Age at index (yr) 69.16±9.75 69.90±8.84 0.008 0.080
 Body mass index (kg/m2) 30.67±6.62 31.27±6.79 0.746 0.090
Race
 American Indian or Alaska Native 10 (0.45) 10 (0.45) 1.000 <0.001
 Asian 15 (0.67) 12 (0.54) 0.563 0.017
 Black/African American 192 (8.60) 167 (7.48) 0.169 0.041
 Native Hawaiian or other Pacific islander 10 (0.45) 10 (0.45) 1.000 <0.001
 White/Caucasian 1,941 (86.92) 2,000 (89.57) 0.006 0.082
 Other race 43 (1.93) 25 (1.12) 0.028 0.066
 Unknown race 30 (1.34) 21 (0.94) 0.205 0.038
 Hispanic or Latino 75 (3.36) 49 (2.19) 0.018 0.071
 Not Hispanic or Latino 1,980 (88.67) 2,011 (90.06) 0.132 0.045
 Unknown ethnicity 178 (7.97) 173 (7.75) 0.781 0.008
HbA1c
 <7.5% 1,488 (66.64) 1,499 (67.13) 0.727 0.010
 ≥7.5% 237 (10.61) 217 (9.72) 0.322 0.030
Medical history
 Disorders of lipoprotein metabolism and other dyslipidemia 1,589 (71.16) 1,636 (73.27) 0.116 0.047
 Overweight and obesity 999 (44.74) 986 (44.16) 0.695 0.012
 Type 2 diabetes mellitus 775 (34.71) 758 (33.95) 0.592 0.016
 Chronic kidney disease 611 (27.36) 585 (26.20) 0.380 0.026
 Tobacco use 80 (3.58) 61 (2.73) 0.104 0.049
 Hypertensive diseases 1,794 (80.34) 1,819 (81.46) 0.341 0.028
 Neoplasms 1,065 (47.69) 1,096 (49.08) 0.353 0.028

Values are presented as number (%) or mean±standard deviation.

HbA1c: hemoglobin A1c.

Table 2.
Rates of surgical complications
Complication Hemophilia Control Odds ratio (95% CI) P-value
Readmission 269 (12.05) 159 (7.12) 1.79 (1.46–2.19) <0.001
Revision surgery 36 (1.61) 20 (0.90) 1.81 (1.05–3.14) 0.031
Periprosthetic joint infection 11 (0.49) ≤10 (0.45) 1.10 (0.47–2.60) 0.827
Bleeding complication 38 (1.70) ≤10 (0.45) 3.85 (1.91–7.74) <0.001

Values are presented as number (%) unless otherwise indicated.

Table 3.
Rates of medical complications
Outcome Hemophilia Control Odds ratio (95% CI) P-value
Deep vein thrombosis 90 (4.03) 20 (0.90) 4.65 (2.85–7.57) <0.001
Pulmonary embolism 80 (3.58) 15 (0.67) 5.49 (3.16–9.57) <0.001
Venous thromboembolism 84 (3.76) 18 (0.81) 4.85 (2.90–8.10) <0.001
Pneumonia 66 (2.96) 27 (1.21) 2.49 (1.58–3.91) <0.001
Acute kidney injury 94 (4.21) 40 (1.79) 1.92 (1.35–2.72) <0.001
Stroke 44 (1.97) 20 (0.90) 2.22 (1.31–4.79) 0.003
Urinary tract infection 103 (4.61) 63 (2.82) 1.67 (1.21–2.29) 0.002
Opioid prescription 2.69±3.97 1.97±2.65 NA <0.001

Values are presented as number (%) or mean±standard deviation unless otherwise indicated.

NA: not applicable.

REFERENCES

1. Mayfield CK, Korber SS, Hwang NM, et al. Volume, indications, and number of surgeons performing reverse total shoulder arthroplasty continue to expand: a nationwide cohort analysis from 2016-2020. JSES Int 2023;7:827-34.
crossref pmid pmc
2. Klug A, Herrmann E, Fischer S, Hoffmann R, Gramlich Y. Projections of primary and revision shoulder arthroplasty until 2040: facing a massive rise in fracture-related procedures. J Clin Med 2021;10:5123.
crossref pmid pmc
3. Best MJ, Aziz KT, Wilckens JH, McFarland EG, Srikumaran U. Increasing incidence of primary reverse and anatomic total shoulder arthroplasty in the United States. J Shoulder Elbow Surg 2021;30:1159-66.
crossref pmid
4. Rabinowitz J, Kothandaraman V, Lin J, Li X, Friedman RJ, Eichinger JK. Utilization of shoulder arthroplasty in the United States – an analysis of current trends and future predictions. Semin Arthroplasty 2020;30:200-9.
crossref
5. Ragland DA, Cecora AJ, Vallurupalli N, et al. Elbow arthroplasty utilization in 2060: projections of primary and revision elbow arthroplasty in the United States in the next 40 years. J Shoulder Elbow Surg 2025;34:130-5.
crossref pmid
6. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost 2021;19:2112-21.
crossref pmid pmc
7. Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb 2011;1:51-9.
crossref pmid pmc
8. Ozelo MC. Surgery in patients with hemophilia: is thromboprophylaxis mandatory? Thromb Res 2012;130 Suppl 1:S23-6.
crossref pmid
9. Cahlon O, Klepps S, Cleeman E, Flatow E, Gilbert M. A retrospective radiographic review of hemophilic shoulder arthropathy. Clin Orthop Relat Res 2004;423:106-11.
crossref
10. Rodriguez-Merchan EC, De la Corte-Rodriguez H, Antuña S, Gomez-Cardero P, Alvarez-Roman MT, Jimenez-Yuste V. Shoulder arthroplasty in hemophilia. Arch Bone Jt Surg 2025;13:164-9.
crossref pmid pmc
11. Gillinov SM, Modrak M, Park N, et al. Total shoulder arthroplasty in patients with hemophilia A: greater odds of postoperative bleeding and thromboembolic events but no difference in 5-year implant survival. Clin Orthop Relat Res 2025;483:268-75.
crossref pmid pmc
12. Rodriguez-Merchan EC, De la Corte-Rodriguez H, Alvarez-Roman T, Gomez-Cardero P, Encinas-Ullan CA, Jimenez-Yuste V. Complications and implant survival of total knee arthroplasty in people with hemophilia. J Clin Med 2022;11:6244.
crossref pmid pmc
13. Buckner TW, Andrew L, Ragni MV, Eyster ME, Kempton CL, Key NS. Postoperative deep vein thrombosis (DVT) in patients with hemophilia undergoing major orthopedic surgery. Blood 2013;122:207.
crossref
14. Kleiboer B, Layer MA, Cafuir LA, et al. Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: a prospective multicenter observational study. J Thromb Haemost 2022;20:857-65.
crossref pmid pmc
15. Santagata D, Abenante A, Squizzato A, et al. Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review. J Thromb Haemost 2024;22:1117-31.
crossref pmid
16. Lung BE, Kanjiya S, Bisogno M, Komatsu DE, Wang ED. Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access 2019;3:183-8.
crossref pmid pmc
17. Saleh HE, Pennings AL, ElMaraghy AW. Venous thromboembolism after Shoulder shoulder arthroplasty: a systematic review. J Shoulder Elbow Surg 2013;22:1440-8.
crossref pmid
18. Chua MJ, Hart AJ, Mittal R, Harris IA, Xuan W, Naylor JM. Early mobilisation after total hip or knee arthroplasty: a multicentre prospective observational study. PLoS One 2017;12:e0179820.
crossref pmid pmc
19. Hermans C. Thrombosis and hemophilia: little more evidence, much more guidance. Hemasphere 2023;7:e918.
crossref
20. Badulescu OV, Badescu MC, Bojan IB, et al. Thrombotic disease in hemophilic patients: Is this a paradox in a state of hypocoagulability? Diagnostics (Basel) 2024;14:286.
crossref
21. Buckner TW, Leavitt AD, Ragni M, et al. Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thromb Haemost 2016;116:42-9.
crossref
22. Ahmed HS, Jayaram PR. Anesthetic considerations for joint replacement surgery in hemophilic arthropathy: a comprehensive review. Anesth Pain Med (Seoul) 2024;19:194-208.
crossref pmid pmc
23. Fortier LM, Rockov ZA, Chen AF, Rajaee SS. Activity recommendations after total hip and total knee arthroplasty. J Bone Joint Surg Am 2021;103:446-55.
crossref
24. Hochberger F, Wild MF, Heinz T, Rudert M, List K. Comparative study on postoperative immobilization in reverse total shoulder arthroplasty: 4 weeks vs. 6 weeks of immobilization yields similar clinical and functional outcomes. J Clin Med 2024;13:6363.
crossref pmid pmc
25. Vendittoli PA, Pellei K, Desmeules F, et al. Enhanced recovery short-stay hip and knee joint replacement program improves patients outcomes while reducing hospital costs. Orthop Traumatol Surg Res 2019;105:1237-43.
crossref
26. Mehta N, Acuna AJ, McCormick JR, et al. Publicly available anatomic total shoulder arthroplasty rehabilitation protocols show high variability and frequent divergence from the 2020 ASSET recommendations. Int J Sports Phys Ther 2024;19:856-67.
crossref pmid pmc
27. Ripoll S-Melchor J, Aldecoa CS, Fernández-García R, et al. Early mobilization after total hip or knee arthroplasty: a substudy of the POWER.2 study. Braz J Anesthesiol 2023;73:54-71.
crossref
28. Choudhury MZ, Mann HA, Goddard NJ, Lee CA. An outline of the current orthopaedic management of haemophilic disease of the upper limb. Haemophilia 2007;13:599-605.
crossref pmid
29. Challoumas D, Munn D, Jeyakumar G, et al. Outcomes of total hip and knee arthroplasty in patients with haemophilia: a meta-analysis of comparative studies and clinical practice recommendations. Haemophilia 2024;30:180-94.
crossref


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#413, 10, Bamgogae-ro 1-gil, Gangnam-gu, Seoul, Republic of Korea
E-mail: journal@cisejournal.org                

Copyright © 2026 by Korean Shoulder and Elbow Society.

Developed in M2PI

Close layer
prev next